Chugai Pharmaceutical
E238175
Chugai Pharmaceutical is a major Japanese research-based pharmaceutical company known for its innovative biopharmaceuticals and strategic alliance with Roche.
All labels observed (5)
| Label | Occurrences |
|---|---|
| Chugai Pharmaceutical canonical | 2 |
| Chugai | 1 |
| Chugai Pharma Europe | 1 |
| Chugai Pharma USA | 1 |
| 中外製薬株式会社 | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T2138505 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
Target entity: Chugai Pharmaceutical Context triple: [Roche, subsidiary, Chugai Pharmaceutical]
-
A.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
-
B.
Roche
Roche is a major Swiss multinational healthcare company and one of the world’s leading pharmaceutical and diagnostics firms.
-
C.
Novartis
Novartis is a global Swiss-based pharmaceutical company known for developing innovative medicines across a wide range of therapeutic areas.
-
D.
AstraZeneca
AstraZeneca is a global biopharmaceutical company known for researching, developing, and manufacturing prescription medicines across areas such as oncology, cardiovascular, respiratory, and immunology.
-
E.
Sanofi
Sanofi is a major French multinational pharmaceutical company known for developing prescription medicines, vaccines, and consumer healthcare products worldwide.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Target entity: Chugai Pharmaceutical Target entity description: Chugai Pharmaceutical is a major Japanese research-based pharmaceutical company known for its innovative biopharmaceuticals and strategic alliance with Roche.
-
A.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
-
B.
Roche
Roche is a major Swiss multinational healthcare company and one of the world’s leading pharmaceutical and diagnostics firms.
-
C.
Novartis
Novartis is a global Swiss-based pharmaceutical company known for developing innovative medicines across a wide range of therapeutic areas.
-
D.
AstraZeneca
AstraZeneca is a global biopharmaceutical company known for researching, developing, and manufacturing prescription medicines across areas such as oncology, cardiovascular, respiratory, and immunology.
-
E.
Sanofi
Sanofi is a major French multinational pharmaceutical company known for developing prescription medicines, vaccines, and consumer healthcare products worldwide.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
pharmaceutical company ⓘ public company ⓘ |
| abbreviation |
Chugai Pharmaceutical
self-linksurface differs
ⓘ
surface form:
Chugai
|
| businessModel | research-based pharmaceutical company ⓘ |
| collaboratesWith | Roche ⓘ |
| country | Japan ⓘ |
| employs | thousands of employees ⓘ |
| engagesIn |
biopharmaceutical manufacturing
ⓘ
clinical development ⓘ drug discovery ⓘ |
| focusesOn |
biopharmaceuticals
ⓘ
hematology medicines ⓘ immunology medicines ⓘ oncology medicines ⓘ |
| foundedBy | Juzo Ueno NERFINISHED ⓘ |
| foundedIn | 1925 ⓘ |
| hasJapaneseName |
Chugai Pharmaceutical
self-linksurface differs
ⓘ
surface form:
中外製薬株式会社
|
| hasProduct |
Actemra
ⓘ
Alecensa ⓘ Hemlibra ⓘ Tecentriq ⓘ |
| hasRAndDCenter |
Fujieda Plant
ⓘ
Kamakura Research Laboratories ⓘ |
| hasStockTicker | 4519 ⓘ |
| hasSubsidiary |
Chugai Pharmaceutical
self-linksurface differs
ⓘ
surface form:
Chugai Pharma Europe
Chugai Pharmaceutical self-linksurface differs ⓘ
surface form:
Chugai Pharma USA
|
| hasTherapeuticArea |
hemophilia
ⓘ
oncology ⓘ rheumatology ⓘ |
| headquartersLocation |
Japan
ⓘ
Tokyo ⓘ |
| industry |
biotechnology
ⓘ
pharmaceutical industry ⓘ |
| isAffiliateOf |
Roche
ⓘ
surface form:
Roche Group
|
| isListedOn | Tokyo Stock Exchange ⓘ |
| knownFor |
innovative biopharmaceuticals
ⓘ
strategic alliance with Roche ⓘ |
| languageOfName | Japanese ⓘ |
| majorShareholder | Roche ⓘ |
| operatesIn |
Asia
ⓘ
Europe ⓘ United States of America ⓘ
surface form:
United States
|
| primaryMarket | Japan ⓘ |
| regulatoryRegion | PMDA Japan ⓘ |
| strategicPartner | Roche ⓘ |
| usesTechnology |
antibody engineering
ⓘ
biologics manufacturing ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Subject: Chugai Pharmaceutical Description of subject: Chugai Pharmaceutical is a major Japanese research-based pharmaceutical company known for its innovative biopharmaceuticals and strategic alliance with Roche.
Referenced by (6)
Full triples — surface form annotated when it differs from this entity's canonical label.